Core Points - Wuhan Huisheng Biotechnology Co., Ltd. has revised its company articles to enhance governance and protect the rights of stakeholders [1][2] - The company was registered on July 27, 2020, and went public on August 24, 2020, with a registered capital of RMB 202.332557 million [1] - The revision includes detailed rules on share management, shareholder rights and obligations, board structure, and management responsibilities [2] Share Management - The total number of shares is 202.332557 million, all of which are ordinary shares [1] - The company has established rules for share issuance, reduction, repurchase, and transfer, ensuring equal rights for the same class of shares [1] - Specific restrictions on share transfer are in place, such as a one-year lock-up period for shares issued before the public offering [1] Shareholder and Shareholder Meeting - The rights and obligations of shareholders, as well as the responsibilities of controlling shareholders and actual controllers, are clearly defined [2] - Shareholders have rights to dividends and participation in shareholder meetings, while also being obligated to comply with the articles and pay share capital [2] - The shareholder meeting has decision-making authority on major company matters, including electing directors and approving profit distribution [2] Board of Directors - The board consists of five directors, including two independent directors and one employee director [2] - The board is accountable to the shareholder meeting and has various powers, including convening meetings and executing resolutions [2] - Detailed responsibilities and operations for independent directors and board committees are outlined [2] Senior Management - The company appoints one general manager and several deputy managers, with clear qualifications and responsibilities for senior management [2] - The articles also cover financial accounting, profit distribution, auditing, and procedures for corporate actions such as mergers and dissolutions [2] Conclusion - The revision of the company articles is a significant step for Huisheng Biotechnology to adapt to its development and market changes, aiming to improve governance and ensure sustainable operations [2]

Group 1 - The company, Huisheng Biological, announced the convening of its third temporary board meeting for the fourth session on October 16, 2025, to discuss the election of committee members [1] - For the fiscal year 2024, the revenue composition of Huisheng Biological is 93.02% from veterinary raw materials and formulations, with the remaining 6.98% from other sources [1] - As of the report date, Huisheng Biological has a market capitalization of 4.2 billion yuan [1]

武汉回盛生物科技股份有限公司 章 程 （本章程经 2025 年第三次临时股东大会审议通过后生效） 二〇二五年九月 | - | . | 7 | 1 | | --- | --- | --- | --- | | 2 | | | | | | | | | | 武汉回盛生物科技股份有限公司 章程 第一章 总则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和行为， 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证 券法》（以下简称《证券法》）、中国证券监督管理委员会（以下简称"中国证 监会"）颁布的《上市公司章程指引》和其他有关规定，制订本章程。 第二条 武汉回盛生物科技股份有限公司系依照《公司法》和其他有关规定成立 的股份有限公司（以下简称"公司"或"本公司"）。 公司是武汉回盛生物科技有限公司以整体变更的方式设立的股份公司；在湖北省 武汉市市场监督管理局注册登记，取得营业执照，统一社会信用代码： 9142011273354032X9。 第三条 公司于 2020 年 7 月 27 日经中国证券监督管理委员会注册，首次向社会 公众发行人民币普通股 2,770 万股，于 2020 年 ...

证券代码：300871 证券简称：回盛生物 公告编号：2025-094 武汉回盛生物科技股份有限公司 2025年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 （2）网络投票时间：2025年10月16日，其中，通过深圳证券交易所交易 系统进行网络投票的具体时间为：2025年10月16日 9:15-9:25、9:30-11:30和 13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间为2025年10 月16日 9:15-15:00。 2、现场会议召开地点：湖北省武汉市武昌区中华路1号306会议室。 3、会议召开方式：本次股东大会采取现场表决与网络投票相结合的方式 召开。同一表决权只能选择现场投票、深圳证券交易所交易系统投票、互联网 投票系统中的一种表决方式，同一表决权出现重复投票表决的，以第一次投票 1、会议召开时间： （1）现场会议召开时间：2025年10月16日（星期四）14:00 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议； 3、本次股东大会审议的议案 ...

国浩律师（深圳）事务所 法律意见书 国浩律师（深圳）事务所 关于武汉回盛生物科技股份有限公司 2025年第三次临时股东大会法律意见书 致：武汉回盛生物科技股份有限公司 国浩律师（深圳）事务所（以下简称"本所"）接受武汉回盛生物科技股份 有限公司（以下简称"公司"）的委托，指派彭瑶律师、季俊宏律师（以下简称 "本所律师"）出席公司2025年第三次临时股东大会（以下简称"本次股东大会" 或"本次会议"），对本次股东大会的合法性进行见证。本所律师根据《中华人 民共和国公司法》（以下简称"《公司法》"）、《上市公司股东会规则》等法 律、法规和规范性文件以及《武汉回盛生物科技股份有限公司章程》（以下简称 "《公司章程》"）的规定，就公司本次股东大会的召集、召开程序、出席会议 人员的资格、召集人的资格、表决程序和表决结果等有关事宜出具本法律意见书。 在本法律意见书中，本所律师仅对本次股东大会的召集、召开程序、出席会 议人员资格、召集人的资格、表决程序以及表决结果是否符合相关法律、法规、 其他规范性文件及《公司章程》的规定发表意见，不对会议审议的议案内容以及 这些议案所表述的事实或数据的真实性及准确性发表意见。 按照律师行 ...

证券代码：300871 证券简称：回盛生物 公告编号：2025-096 武汉回盛生物科技股份有限公司 关于董事会换届选举完成及聘任高级管理人员、证券事务代表 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 武汉回盛生物科技股份有限公司（以下简称"公司"）于 2025 年 10 月 16 日召开 2025 年第三次临时股东大会，审议通过了《关于董事会换届暨选举 第四届董事会非独立董事的议案》《关于董事会换届暨选举第四届董事会独立 董事的议案》，选举产生了第四届董事会非职工代表董事，与公司职工代表大 会选举产生的第四届董事会职工代表董事周健女士，共同组成公司第四届董事 会。同日，公司召开第四届董事会第一次会议，选举产生了第四届董事会董事 长、各专门委员会委员，聘任了公司高级管理人员及证券事务代表。现将有关 情况公告如下： 一、第四届董事会及各专门委员会的组成情况 （一）第四届董事会的组成情况 非独立董事：张卫元先生（董事长）、刘泽祥先生 独立董事：冉明东先生、汪明先生 职工代表董事：周健女士 公司第四届董事会由 5 名董事组成，其中独立董事 2 名，职工代 ...

第四届董事会第一次会议决议公告 证券代码：300871 证券简称：回盛生物 公告编号：2025-095 武汉回盛生物科技股份有限公司 （一）审议通过了《关于选举第四届董事会董事长的议案》 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 根据《公司法》《公司章程》等有关规定，公司全体董事一致同意选举张 卫元先生担任公司第四届董事会董事长，任期三年，自本次董事会审议通过之 日起至第四届董事会任期届满之日止。 具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）上披露的《关于董 事会换届选举完成及聘任高级管理人员、证券事务代表的公告》（公告编号： 1 2025-096）。 表决结果为：同意 5 票；反对 0 票；弃权 0 票。本议案获得通过。 一、董事会会议召开情况 武汉回盛生物科技股份有限公司（以下简称"公司"）于 2025 年 10 月 16 日召开的 2025 年第三次临时股东大会选举产生的第四届董事会非职工代表 董事，以及于 2025 年 9 月 28 日召开的 2025 年第一次职工代表大会选举产生 的第四届董事会职工代表董事，共同组成第四届 ...

Group 1 - The core viewpoint of the news is that Huisheng Biological has experienced fluctuations in its stock price and trading volume, with a significant increase in stock price year-to-date, but recent declines in the short term [1] - As of October 16, Huisheng Biological's stock price was 20.92 yuan per share, with a market capitalization of 4.233 billion yuan and a trading volume of 80.2648 million yuan [1] - The company has seen a net outflow of main funds amounting to 2.2558 million yuan, with large orders showing a mixed buying and selling pattern [1] Group 2 - Huisheng Biological operates primarily in the veterinary medicine sector, with 93.56% of its revenue coming from veterinary raw materials and formulations [1] - As of June 30, the number of shareholders increased by 65.21% to 23,500, while the average number of circulating shares per person decreased by 28.44% [2] - For the first half of 2025, Huisheng Biological reported a revenue of 822 million yuan, representing a year-on-year growth of 88.45%, and a net profit attributable to shareholders of 117 million yuan, up 325.88% year-on-year [2] Group 3 - Since its A-share listing, Huisheng Biological has distributed a total of 236 million yuan in dividends, with 135 million yuan distributed over the past three years [3]

Core Viewpoint - The company, Huisheng Biological (300871), is actively expanding its overseas market presence, primarily focusing on the export of raw materials, while its formulation business is still in the exploratory phase [2]. Group 1: Stock Performance - As of October 15, 2025, Huisheng Biological's stock closed at 21.35 yuan, an increase of 1.47%, with a turnover rate of 2.25%, a trading volume of 45,500 shares, and a transaction amount of 96.5641 million yuan [1]. Group 2: Investor Relations - The company has received inquiries regarding its competitiveness in overseas markets and its strategies for international expansion, indicating a positive trend in overseas sales [2]. - The company has not yet provided a third-quarter earnings forecast, with the report scheduled for release on October 28 [2]. - The company is awaiting approval from the China Securities Regulatory Commission for its targeted stock issuance, with the review inquiry response already submitted [2]. Group 3: Market Activity - On October 15, there was a net inflow of 1.2384 million yuan from major funds, suggesting increased short-term interest in Huisheng Biological [2]. - Retail investors showed a net outflow of 1.9195 million yuan, while speculative funds had a net inflow of 0.6811 million yuan [2].

Group 1 - The company is actively expanding its overseas market presence, with positive sales growth in its international business [2] - The primary component of the overseas business is the export of active pharmaceutical ingredients (APIs), while the formulation export business is still in the exploratory phase [2]